D’orthoclone au dénosumab - L’expansion des anticorps monoclonaux à des fins thérapeutiques

Jacques Biot; Christelle Fasano; Céline Dos Santos

doi:10.1051/medsci/200925121177

Accueil

Tous les numéros

Volume 25 / Numéro 12 (Décembre 2009)

Med Sci (Paris), 25 12 (2009) 1177-1182

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 25, Numéro 12, Décembre 2009 Anticorps monoclonaux en thérapeutique


Page(s)		1177 - 1182
Section		III - Un futur en développement
DOI		https://doi.org/10.1051/medsci/200925121177
Publié en ligne		15 décembre 2009

Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30. [Google Scholar]
Beck A, Wurch T, Corvaïa N. Therapeutic antibodies and derivatives : from the bench to the clinic. Curr Pharm Biotechnol 2008; 9 : 421–2. [Google Scholar]
Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. mAbs 2009; 1 : 1–11. [Google Scholar]
Reichter J. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007; 21 : 1–7. [Google Scholar]
Aggarwal S. What’s fueling the biotech engine-2007. Nat Biotechnol 2008; 26 : 1227–33. [Google Scholar]
Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 : 3992–5. [Google Scholar]
Sheridan C. EGFR inhibitors embrace KRAS. Nat Biotechnol 2008; 26 : 839–40. [Google Scholar]
Rosenfeld PJ. Intravitreal avastin : the low cost alternative to lucentis ? Am J Ophthalmol 2006; 142 : 141–3. [Google Scholar]
Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355 : 1409–12. [Google Scholar]
Dobson R. NICE introduces cost sharing scheme for sight drug. Br Med J 2008; 337 : a1487. doi : 10.1136/bmj.a1487. [Google Scholar]
Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26 : 985–90. [Google Scholar]
Moon JY, Kim W, Kim JH, et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J 2008; 49 : 389–99. [Google Scholar]
http://www.emea.europa.eu/pdfs/human/biosimilar/49340805en.pdf [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30. [Google Scholar]

[2] Beck A, Wurch T, Corvaïa N. Therapeutic antibodies and derivatives : from the bench to the clinic. Curr Pharm Biotechnol 2008; 9 : 421–2. [Google Scholar]

[3] Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. mAbs 2009; 1 : 1–11. [Google Scholar]

[4] Reichter J. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007; 21 : 1–7. [Google Scholar]

[5] Aggarwal S. What’s fueling the biotech engine-2007. Nat Biotechnol 2008; 26 : 1227–33. [Google Scholar]

[6] Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 : 3992–5. [Google Scholar]

[7] Sheridan C. EGFR inhibitors embrace KRAS. Nat Biotechnol 2008; 26 : 839–40. [Google Scholar]

[8] Rosenfeld PJ. Intravitreal avastin : the low cost alternative to lucentis ? Am J Ophthalmol 2006; 142 : 141–3. [Google Scholar]

[9] Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355 : 1409–12. [Google Scholar]

[10] Dobson R. NICE introduces cost sharing scheme for sight drug. Br Med J 2008; 337 : a1487. doi : 10.1136/bmj.a1487. [Google Scholar]

[11] Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26 : 985–90. [Google Scholar]

[12] Moon JY, Kim W, Kim JH, et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J 2008; 49 : 389–99. [Google Scholar]

[13] http://www.emea.europa.eu/pdfs/human/biosimilar/49340805en.pdf [Google Scholar]